<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03856047</url>
  </required_header>
  <id_info>
    <org_study_id>NN9838-4433</org_study_id>
    <secondary_id>U1111-1214-0429</secondary_id>
    <secondary_id>2018-001945-14</secondary_id>
    <nct_id>NCT03856047</nct_id>
  </id_info>
  <brief_title>Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.</brief_title>
  <official_title>Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at the change in body weight in people taking NNC0174-0833, liraglutide
      and &quot;dummy&quot; medicine, from the start to the end of the study. As well as taking the medicine,
      participants will have talks with study staff about healthy food choices, how to be more
      physically active and what participants can do to lose weight. Participants will either take
      NNC0174-0833, liraglutide or &quot;dummy&quot; medicine - which treatment participants get is decided
      by chance. Participants will need to take one injection once a week or once a day, depending
      on the treatment. The study medicine is injected with a thin needle in a skin fold in the
      stomach, thigh or upper arm. The study will last for about 8 months. Participants will have
      12 clinic visits with the study doctor.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">April 9, 2021</completion_date>
  <primary_completion_date type="Actual">March 2, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a twelve-armed trial comprising of five (0.3, 0.6, 1.2, 2.4 and 4.5 mg OW) of NNC0174-0833 arms and liraglutide 3.0 mg OD arm as active treatment arms and the corresponding 6 placebo arms as comparators. Participants will be randomised 6:1 between the active treatment arms and the placebo arms. The five different NNC0174-0833 placebo arms and the one liraglutide placebo arm will be pooled into one placebo group for statistical analyses of the results.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Sponsor staff involved in the clinical trial is masked according to company standard procedures.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Percent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects who achieve 5 percent or more body weight reduction (yes/no)</measure>
    <time_frame>Week 26</time_frame>
    <description>Percentage of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects who achieve 10 percent or more body weight reduction (yes/no)</measure>
    <time_frame>Week 26</time_frame>
    <description>Percentage of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight (kg)</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference (cm)</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting lipids - total cholesterol</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting lipids - high density lipoprotein (HDL) cholesterol</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting lipids - low density lipoprotein (LDL) cholesterol</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting lipids - very low density lipoprotein (VLDL) cholesterol</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting lipids - triglycerides</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glycosylated haemoglobin (HbA1c)</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in percentage-points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG)</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting insulin.</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in μIU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostatic model assessment of insulin resistance (HOMA-IR)</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in percentage-points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostatic model assessment of β-cell function (HOMA-β)</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in percentage-points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs) from randomisation to end of trial</measure>
    <time_frame>Week 0-32</time_frame>
    <description>Measured in number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent serious adverse events (SAEs)</measure>
    <time_frame>Week 0-32</time_frame>
    <description>Measured in number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-drug antibodies towards NNC0174-0833 (yes/no)</measure>
    <time_frame>Week 0-32</time_frame>
    <description>Percentage of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic blood pressure</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean 24-hour systolic blood pressure</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean 24-hour diastolic blood pressure</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulse</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in high sensitivity C-Reactive Protein (hsCRP)</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasminogen activator inhibitor-1 (PAI-1) activity</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renin activity</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in g/mL/h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aldosterone</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in ng/dL</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">706</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>NNC0174-0833, 4.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 4.5 mg of NNC0174-0833 once a week as injections for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC0174-0833, 2.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 2.4 mg of NNC0174-0833 once a week as injections for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC0174-0833, 1.2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 1.2 mg of NNC0174-0833 once a week as injections for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC0174-0833, 0.6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 0.6 mg of NNC0174-0833 once a week as injections for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC0174-0833 0.3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 2.4 mg (NNC0174-0833)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 2.4 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 4.5 mg (NNC0174-0833)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 4.5 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 1.2 mg (NNC0174-0833)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 1.2 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 0.6 mg (NNC0174-0833)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 0.6 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 0.3 mg (NNC0174-0833)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 3.0 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 3.0 mg of liraglutide once daily as injections for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 3.0 mg (Liraglutide)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo 3.0 mg(liraglutide) once daily as injections for 26 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0174-0833</intervention_name>
    <description>Participants will get one dose of NNC0174-0833 once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.</description>
    <arm_group_label>NNC0174-0833 0.3 mg</arm_group_label>
    <arm_group_label>NNC0174-0833, 0.6 mg</arm_group_label>
    <arm_group_label>NNC0174-0833, 1.2 mg</arm_group_label>
    <arm_group_label>NNC0174-0833, 2.4 mg</arm_group_label>
    <arm_group_label>NNC0174-0833, 4.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (NNC0174-0833)</intervention_name>
    <description>Participants will get one dose of Placebo (NNC0174-0833) once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.</description>
    <arm_group_label>Placebo 0.3 mg (NNC0174-0833)</arm_group_label>
    <arm_group_label>Placebo 0.6 mg (NNC0174-0833)</arm_group_label>
    <arm_group_label>Placebo 1.2 mg (NNC0174-0833)</arm_group_label>
    <arm_group_label>Placebo 2.4 mg (NNC0174-0833)</arm_group_label>
    <arm_group_label>Placebo 4.5 mg (NNC0174-0833)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide 3.0 mg</intervention_name>
    <description>Participants will get one dose of liraglutide 3.0 mg once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg daily. The participants will continue on 3.0 mg of liraglutide, once daily up to 26 weeks.</description>
    <arm_group_label>Liraglutide 3.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Liraglutide 3.0 mg)</intervention_name>
    <description>Participants will get one dose of Placebo (liraglutide 3.0 mg) once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg. The participants will continue on Placebo (liraglutide 3.0 mg), once daily up to 26 weeks.</description>
    <arm_group_label>Placebo 3.0 mg (Liraglutide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older at the time of signing the informed consent.

          -  Female subject of non-childbearing potential or Male subject who is surgically
             sterilised (vasectomy) or who is willing to use adequate contraceptive methods (as
             required by local regulation or practice) throughout the trial (until 'end of trial').

          -  BMI equal to 30.0 kg/m^2 or greater or BMI equal to 27.0 kg/m^2 or greater with the
             presence of at least one of the following weight-related comorbidities (treated or
             untreated): hypertension or dyslipidaemia (to be assessed at the investigator's
             discretion).

        Exclusion Criteria:

          -  HbA1c equal to 48 mmol/mol (6.5 percentage) or greater as measured by the central
             laboratory at screening.

          -  A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days prior
             to screening irrespective of medical records.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Reporting Anchor and Disclosure (1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Crystal River</city>
        <state>Florida</state>
        <zip>34429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075-6437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040-6815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wadsworth</city>
        <state>Ohio</state>
        <zip>44281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620-7352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2T 5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2V 4J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6H 2L4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jyväskylä</city>
        <zip>40620</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>University Of Helsinki</city>
        <zip>00014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Galway</city>
        <zip>H91 YR71</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>103-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-281</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-001</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-589</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Boksburg</city>
        <state>Gauteng</state>
        <zip>1466</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1812</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4450</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bradford-on-Avon</city>
        <zip>BA15 1DQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <zip>WC1E 6JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rotherham</city>
        <zip>S65 1DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Ireland</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

